Int J Cardiovasc Imag:陈绍良等Meta分析称,血管内超声指导支架置入,可大幅减少不良事件

2019-02-17 朱柳媛 中国循环杂志

近日,南京第一医院陈绍良教授等人发表的一项Meta分析表明,在为冠心病患者施行药物洗脱支架置入术时,与以冠脉造影结果指导手术相比,用血管内超声(IVUS)指导手术可显著降低心原性死亡、冠脉血运重建、支架内血栓形成等事件的发生风险。

近日,南京第一医院陈绍良教授等人发表的一项Meta分析表明,在为冠心病患者施行药物洗脱支架置入术时,与以冠脉造影结果指导手术相比,用血管内超声(IVUS)指导手术可显著降低心原性死亡、冠脉血运重建、支架内血栓形成等事件的发生风险。

研究者从Medline、Scopus、Google Scholar、Cochrane Controlled TrialsRegistry等数据库搜集到9项符合条件的相关随机对照研究,共分析了4724例患者资料。平均随访16.7年,接受IVUS指导药物洗脱支架置入术的患者中主要不良血管事件减少39%、心原性死亡减少51%、靶血管血运重建减少42%、靶病变血运重建减少41%、支架血栓形成减少55%。两组在全因死亡和心肌梗死发生风险上无明显差异。

亚组分析表明,在用IVUS指导药物洗脱支架置入的患者中,达到最佳手术标准的患者中主要不良心血管事件的发生风险比未达最佳手术标准的患者降低了67%。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1887997, encodeId=e595188e997fd, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Oct 10 11:41:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896466, encodeId=19c9189646676, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 20 18:41:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938921, encodeId=44f0193892174, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 23 08:41:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360870, encodeId=009e3608e08b, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2712531442, createdName=人民公仆老金, createdTime=Sun Feb 17 16:44:06 CST 2019, time=2019-02-17, status=1, ipAttribution=)]
    2019-10-10 guojianrong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1887997, encodeId=e595188e997fd, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Oct 10 11:41:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896466, encodeId=19c9189646676, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 20 18:41:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938921, encodeId=44f0193892174, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 23 08:41:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360870, encodeId=009e3608e08b, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2712531442, createdName=人民公仆老金, createdTime=Sun Feb 17 16:44:06 CST 2019, time=2019-02-17, status=1, ipAttribution=)]
    2019-07-20 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1887997, encodeId=e595188e997fd, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Oct 10 11:41:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896466, encodeId=19c9189646676, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 20 18:41:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938921, encodeId=44f0193892174, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 23 08:41:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360870, encodeId=009e3608e08b, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2712531442, createdName=人民公仆老金, createdTime=Sun Feb 17 16:44:06 CST 2019, time=2019-02-17, status=1, ipAttribution=)]
    2019-11-23 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1887997, encodeId=e595188e997fd, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Oct 10 11:41:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896466, encodeId=19c9189646676, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 20 18:41:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938921, encodeId=44f0193892174, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 23 08:41:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360870, encodeId=009e3608e08b, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2712531442, createdName=人民公仆老金, createdTime=Sun Feb 17 16:44:06 CST 2019, time=2019-02-17, status=1, ipAttribution=)]
    2019-02-17 人民公仆老金

    厉害了

    0

相关资讯

Int J Cardiol:非肥胖和肥胖2型糖尿病合并冠心病患者的血糖控制策略

由此可见,在患有2型糖尿病和CAD的非肥胖患者中,IS治疗策略可能比IP治疗策略更有益。

JACC:冠心病伴糖尿病患者冠脉搭桥远期死亡率低于介入治疗

FREEDOM临床研究结果显示对于伴有多支冠脉病变(MVD)的糖尿病患者, 随访3.8年后,冠脉搭桥手术(CABG)在减少主要心脑血管不良事件方面要优于药物洗脱支架的介入治疗(PCI-DES)。本研究的目的旨在比较FREEDOM临床研究中伴MVD糖尿病患者的远期预后。FREEDOM临床研究将1900例患者随机分成PCI-DES组和CABG组,研究结束后又邀请参与者进行随访研究。最终,共有来自25个

ATVB:血细胞膜脂肪酸与冠心病发病率的关系

由此可见,较高水平的C22:0和C24:0与较低的CHD发病率相关,而较高水平的C20:1n9与较高的DHD风险相关。这项研究为不同类型的循环饱和脂肪酸对心血管疾病影响存在潜在差异增添了越来越多的证据。

Stroke:人工加糖饮料与卒中、冠心病和全因死亡率的关系

由此可见,ASB摄入量增加与卒中风险增加有关,特别是小动脉闭塞亚型、冠心病和全因死亡率。研究虽然需要重复,但这些新发现增加了大量摄入ASB与这些健康结局潜在的有害关联。

2018 ESC意见书:抑郁和冠心病

2019年1月,欧洲心脏病学会(ESC)发布了抑郁和冠心病的意见书。抑郁症是一种非常常见的情况,约有10%的人群受其影响,已经逐渐成为全球性的问题。本文主要总结了冠心病抑郁相关的关键因素,主要目的是提高临床意识,改善管理。

JACC:女性冠心病患者的冠脉功能不全与不良预后相关

目前,近一半疑似有心梗的女性并无冠脉梗阻性疾病(CAD),反倒是冠脉的反应性异常(CR)比较常见。本研究的目的旨在评估和比较有或无CAD女性的CR发生率和远期不良心血管结局(MACE)。本研究纳入了224名有症状的冠心病女性患者,并对其进行了CR检测,经过平均9.7年时间的随访,共有129例不良心血管事件发生,低冠状动脉血流储备是MACE增高的预测因子([HR]: 1.06; 95% [CI]: